Supplementary Files
Keywords
How to Cite
Abstract
Objective: Preterm birth (PTB) occurs between 24-37 weeks of gestation. The important risk factor for PTB is a previous PTB and currently progesterone is used for the management of recurrent spontaneous PTB. Some studies have shown good outcomes but recent studies revealed that the use of vaginal progesterone was not related to a decreased likelihood of PTB or neonatal adverse effects. Thus, the controversy in the literature suggests multiple underlying pathological mechanisms involved in the progression of PTB. This study aims to determine the role of low-dose aspirin in the prevention of preterm birth in patients with a previous history of preterm delivery.
Methodology: In this randomized controlled trial, a total of 172 patients fulfilling the inclusion criteria were selected from the inpatient and outpatient departments. Patients were divided randomly into two groups (group A and group B), using random number tables. In Group A, low-dose aspirin (75mg) was given while group B was taken as a control group. Patients were called every 8 weeks in the outpatient department for the assessment of compliance and side effects of the drug. The data were entered and analyzed by using SPSS v25.0. Chi-square was used to compare the two groups for incidence of preterm birth. Relative risk (along with a 95% confidence interval) for the decrease in the incidence of preterm birth with the use of aspirin was calculated.
Results: The age of participants included in the study was 18 to 40 years. The mean age of patients in group A was 33.85±5.210 years and in group B was 32.86±4.139 years. The mean fetal birth weight in group A was 2281.1962±363.125 grams and in group B was 2271.4344±374.797 grams. In the low-dose aspirin group, 10(11.6%) had preterm birth and 31(36.0%) in the control group with a p-value of 0.001, which is statistically significant. The risk of having preterm birth with low-dose aspirin was 1.801 times less than controls.
Conclusion: aspirin in low dose given before 14 weeks of gestation decrease spontaneous preterm birth as compared to the control group in a woman with a history of previous preterm birth which was spontaneous
References
Ashraf S, Imtiaz I. Role of hydroxyprogesterone caproate injection in prevention of preterm labour in high-risk patients for preterm delivery. Professional Med J. 2019;26(08):1242-5.
Visser L, de Boer MA, de Groot CJ, Nijman TA, Hemels MA, Bloemenkamp KW, et al. Low dose aspirin in the prevention of recurrent spontaneous preterm labour–the APRIL study: a multicenter randomized placebo-controlled trial. BMC pregnancy and childbirth. 2017;17(1):1-7.
Van Vliet EO, Askie LA, Mol BW, Oudijk MA. Antiplatelet agents and the prevention of spontaneous preterm birth. Obstet Gynecol. 2017;129(2):327-36.
Norman JE, Marlow N, Messow CM, Shennan A, Bennett PR, Thornton S, et al. Vaginal progesterone prophylaxis for preterm birth (the OPPTIMUM study): a multi-centre, randomized, double-blind trial. The lancet. 2016;387(10033):2106-16.
Andrikopoulou M, Purisch SE, Handal-Orefice R, Gyamfi-Bannerman C. Low-dose aspirin is associated with reduced spontaneous preterm birth in nulliparous women. Am J Obstet Gynecol. 2018;219(4):399-1.
Hoffman MK, Goudar SS, Kodkany BS, Metgud M, Somannavar M, Okitawutshu J, et al. Low-dose aspirin for the prevention of preterm delivery in nulliparous women with a singleton pregnancy (ASPIRIN): a randomised, double-blind, placebo-controlled trial. The Lancet. 2020;395(10220):285-93.
Silver RM, Ahrens K, Wong LF, Perkins NJ, Galai N, Lesher LL, Faraggi D, Wactawski-Wende J, Townsend JM, Lynch AM, Mumford SL. Low-dose aspirin and preterm birth: a randomized controlled trial. Obstet Gynecol. 2015;125(4):876.
Kupka EJ, Hesselman S, Hastie R, et al. Low dose aspirin use in pregnancy and the risk of preterm birth, a Swedish register-based Cohort study. Am J Obstet Gynecol 2023; 228:336 e 1-9. https://doi.org/10.1016/j.ajog.2022.09.006
Hodgetts Morton V, Stock SJ. Low dose aspirin for the prevention of preterm birth: More questions than answers. PLOS Med 2022; 19:e1003908. https://doi.org/10.1371/journal.pmed.1003908
Petrou S, Yiu HH, Kwon J. Economic consequences of preterm birth: A systematic review of the recent literature (2009-2017). Arch Dis Child. 2019; 104 (5): 456-65. https://doi.org/10.1136/archdischild-2018-315778PMID:30413489
Tingleff T, Vikanes A, Raisanen S, Sandvik L, Murzakanova G, Laine K. Risk of preterm birth in relation to history of preterm birth: A population-based registry study of 213 335 women in Norway. BJOG 2022; 129: 900-7.
Marinovich ML, Regan AK, Gissler M, et al. Association between inter pregnancy interval and preterm birth by previous preterm birth status in four high income countries: A Cohort study. BJOG 2021; 128: 1134-43.
Duley L, Meher S, Hunter KE, Seidler AL, Askie LM. Anit platelet agents for preventing pre-eclampsia and its complications. Cochrane Database Syst Rev 2019; 2019: CD 004659.
US Preventive Services Task Force, Davidson KW, Barry MJ, Mangione CM, Cabana M, Caughey AB, et al. Aspirin use to prevent pre-eclampsia and related morbidity and mortality: US Preventive Services Task Force Recommendation Statement. JAMA. 2021; 326 (12): 1186-91. https://doi.org/10.1001/jama2021.14781PMID:34581729
Allshouse AA, Jessel RH, Heyborne KD. The impact of low-dose aspirin on preterm birth: secondary analysis of a randomized controlled trial. J Perinatol. 2016; 36:427–32.
Rolnik DL, Wright D, Poon LC, et al. Aspirin versus placebo in pregnancies at high risk for preterm preeclampsia. N Engl J Med. 2017; 377:613–22.
Hastie R, Tong S, Wikstrom AK, Sandstrom A, Hesselman S, Bergman L. Aspirin use during pregnancy and the risk of bleeding complications: A Swedish population based Cohort study. Am J Obstet Gynecol 2021; 224: 95.e 1-12.
World Health Organization. WHO recommendations on anti platelet agents for the prevention of pre-eclampsia. 2021. https://www.who.int/publications-detail-redirect/9789240037540.Acceessed December 22,2021.
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
Copyright (c) 2023 Maliha Sadaf, Aasia Saleem, Tallat Farkhanda, Khansa Iqbal, Sabeen Ashraf, Amna Iftikhar